Scipher Medicine Announces Collaboration with Top-Three Pharmaceutical Company to Integrate Precision Medicine into Clinical Trial Design
PrismRA is designed to analyze a patient's molecular profile to predict non-response to certain therapies, enabling a more precise understanding of patient populations. By applying PrismRA within the context of this clinical trial, Scipher Medicine will provide critical insights into therapy response segmentation. These insights are expected to help refine patient selection strategies, better characterize treatment effects across subpopulations, and inform the design of future studies.
This collaboration highlights the growing recognition of the value of precision medicine diagnostics in enhancing the efficiency and effectiveness of the drug development lifecycle. By prospectively or retrospectively analyzing patient data using advanced molecular tools like PrismRA, pharmaceutical companies can gain deeper biological insights that may substantially de-risk and accelerate the path from clinical trial to patient benefit.
"We are incredibly pleased to partner with one of the world's leading pharmaceutical companies to embed precision medicine insights directly into their clinical trial process," said Reg Seeto, CEO of Scipher Medicine. "This collaboration exemplifies our commitment to driving precision medicine into drug development. By applying our validated diagnostic capabilities like PrismRA, we aim to help our partners better understand therapy response, optimize trial design, and ultimately bring the right therapies to the right patients more efficiently."
Scipher Medicine leverages a robust suite of capabilities, including its AI-driven target selection and ranking methodologies, therapy response/non-response biomarker and diagnostic development, and its industry-leading clinico-transcriptomic data asset, to drive innovation across the entire therapeutic development spectrum. This partnership is a testament to the increasing adoption of these advanced approaches by leaders in the pharmaceutical industry.
The specific terms of the collaboration were not disclosed.
About Scipher Medicine
Scipher Medicine is driving the probability of success at each stage of drug development from discovery to commercialization by leveraging AI with network biology, and proprietary data, through our SPECTRA Rx and Dx platforms. Scipher has the industry's largest non-oncology clinico- genomic data asset and biobank in addition to EMR data for over 3 million rheumatology patients. For more information, please visit www.sciphermedicine.com.
About PrismRA®
PrismRA is a revolutionary blood test bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally. From a routine blood draw, the PrismRA test analyzes an individual's molecular signature, helping identify who is unlikely to adequately respond to TNFi therapy, the world's largest selling drug class, so non-responders can be prescribed alternative effective therapy and avoid unnecessary dose escalations or drug cycles. Providers now have objective data to inform therapeutic decision-making and give patients the best chance of achieving treatment targets and improving clinical outcomes. For more information, please visit PrismRA.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
21 minutes ago
- Business Wire
Digi International to Release Third Fiscal Quarter 2025 Earnings Results and Host a Conference Call on August 6, 2025
MINNEAPOLIS--(BUSINESS WIRE)--Digi International® Inc. (NASDAQ: DGII) will release its financial results for the third fiscal quarter 2025 on Wednesday, August 6, after market close, at approximately 4:00 p.m. ET. Ron Konezny, CEO, and Jamie Loch, CFO, will host a conference call later the same day, at 5:00 p.m. ET, to briefly discuss the results and will take questions and provide answers. Please click here to pre-register for the conference call and obtain your dial in number and passcode. All participants are asked to dial-in 15 minutes prior to the start time. Participants may access a live webcast of the conference call through the investor relations section of Digi's website, or the hosting website here. A replay will be available within approximately two hours after the completion of the call. You may access the replay via webcast through the investor relations section of Digi's website. The webcast will be available for replay for approximately one year. About Digi International Delivering Scalable Solutions for What's Next Since 1985, Digi International Inc. (Digi) has been a pioneer in wireless communication, forging the future for connected devices and responding to the needs of the people and enterprises that use them. Before the Internet of Things was a thing, we built M2M and IoT devices, adapted to evolving network standards, and optimized data communications around the most advanced protocols and emerging technologies. From radio frequency modems to gateways, cellular routers, networking devices, embedded system-on-modules (SOM) and single-board computers (SBCs), Digi's solutions have continually grown to serve an extensive breadth of applications across the IoT landscape. Today, our IoT offering includes sensor-based solutions, a sophisticated platform for remotely monitoring device deployments of any size, anywhere, as well as professional design, implementation and certification teams to help you carry out your vision, no matter how large or small. For more information, visit Digi's website at
Business Wire
an hour ago
- Business Wire
Acadia Healthcare Announces Date for Second Quarter 2025 Earnings Release
FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its second quarter 2025 results on Tuesday, August 5, 2025, after the close of the market. Acadia will conduct a conference call with institutional investors and analysts at 9:00 a.m. ET on Wednesday, August 6, 2025. A live broadcast of the conference call will be available at in the 'Investors' section of the website. The webcast of the conference call will be available for 30 days. About Acadia Healthcare Acadia is a leading provider of behavioral healthcare services across the United States. As of March 31, 2025, Acadia operated a network of 270 behavioral healthcare facilities with approximately 12,000 beds in 39 states and Puerto Rico. With approximately 25,500 employees serving more than 82,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.
Business Wire
an hour ago
- Business Wire
EVs Like the VinFast VF 8 Are Changing How We Live, Including How We Road Trip
MARKHAM, Ontario--(BUSINESS WIRE)-- Once doubted as road-trip-worthy, electric vehicles like the VinFast VF 8 are now powering thousands of kilometers across North America, as drivers from Ontario to Florida discover comfort, savings, and a growing EV travel community. A decade ago, suggesting an electric vehicle (EV) for a cross-country road trip, one of North America's most cherished pastimes, would have earned you puzzled looks. Critics scoffed and dismissed EVs as fancy toys meant only for short commutes. But things have changed. Today, 45 percent of EV owners report facing no challenges at all while road-tripping 1. One factor behind this shift is the arrival of reliable, long-range electric vehicles like the mid-sized VinFast VF 8, which offers a driving range of up to 412 kilometers. With a starting MSRP of CAD $53,600, this all-wheel-drive SUV offers comfort, modern technology, and an industry-leading vehicle warranty of ten years or 200,000 kilometers. A community is forming around shared experiences with VinFast and the VF 8. Owners exchange tips, share routes, and offer real-time updates. In one recent post on a VinFast-dedicated Facebook group, M. M., a new EV owner in Canada, got to know his VF 8 through first-hand experience. His first electric road trip took him from Hamilton, Ontario to New York City, covering 2,000 kilometers. 'This was my first time taking an EV on a road trip,' M. M. said. He admitted to having initial difficulties juggling multiple apps to locate chargers. However, the charging itself was not a problem for the VF 8 2. 'Waiting for the car to charge was never an issue,' he explained. The numbers made sense as well. Charging cost him $280 CAD, compared to his estimate of $330 CAD in fuel for the same trip in his previous gas-powered car. The VF 8 saved money and delivered what he described as a 'good driving experience'. Another VF 8 owner, M. B., took on an even longer journey with a round trip from Montreal to Orlando. He covered over 5,000 kilometers on North American highways, including long stretches on Interstate 95 where truckers often drive at high speeds. As an experienced EV driver, he planned his trip using a mix of navigation apps, charging memberships, and backup charging options. The VF 8's comfortable interior played a key role during the long drive, with supportive back seats, strong air conditioning, and ventilated seating helping to keep fatigue at bay. The vehicle performed reliably throughout the journey. Other VF 8 owners have pushed the vehicle even further, including coast-to-coast and multi-state road trips. One feature that stood out in these long-distance travels is the VF 8's advanced driver assistance system. By keeping the vehicle centered and managing acceleration on highways, it reduces the physical strain of long hours behind the wheel and helps drivers feel more refreshed at the end of the day. These real-world journeys show what the VF 8 is capable of on the road. They also reflect the growing confidence among EV drivers who are learning and adapting together. The average EV owner might only take two long-distance trips per year. But when the time comes, the VinFast VF 8 is ready.
